Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHA:603811)
China
· Delayed Price · Currency is CNY 11.71
-0.08 (-0.68%)
Mar 11, 2026, 10:54 AM CST
SHA:603811 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 788.8 | 712.31 | 669.61 | 653.25 | 693.45 | 757.43 | Upgrade
|
| Other Revenue | 2.06 | 2.06 | 2.01 | 1.72 | 0.52 | 0.7 | Upgrade
|
| Revenue | 790.86 | 714.37 | 671.63 | 654.97 | 693.96 | 758.13 | Upgrade
|
| Revenue Growth (YoY) | 7.94% | 6.36% | 2.54% | -5.62% | -8.46% | 11.29% | Upgrade
|
| Cost of Revenue | 237.27 | 225.17 | 248.45 | 217.8 | 208.98 | 206.41 | Upgrade
|
| Gross Profit | 553.59 | 489.2 | 423.17 | 437.17 | 484.99 | 551.72 | Upgrade
|
| Selling, General & Admin | 325.25 | 308.66 | 246.92 | 269.61 | 280.27 | 344.57 | Upgrade
|
| Research & Development | 41.86 | 47.08 | 47.14 | 44.3 | 39.72 | 31.79 | Upgrade
|
| Other Operating Expenses | 17.25 | 12.34 | 7.46 | 7.77 | 10.7 | 9.68 | Upgrade
|
| Operating Expenses | 383.71 | 365.77 | 302.46 | 321.83 | 331.21 | 387.13 | Upgrade
|
| Operating Income | 169.88 | 123.43 | 120.71 | 115.34 | 153.78 | 164.59 | Upgrade
|
| Interest Expense | -5.79 | -11.09 | -15.26 | -9.13 | -4.52 | -4.96 | Upgrade
|
| Interest & Investment Income | 40.62 | 46.28 | 67.12 | 49.08 | 31.87 | 24.36 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.01 | 0.01 | -0.17 | 3.45 | 5.36 | -0.62 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.13 | -0.07 | -0.31 | -0.11 | -0.99 | -0.21 | Upgrade
|
| EBT Excluding Unusual Items | 204.59 | 158.56 | 172.1 | 158.62 | 185.49 | 183.16 | Upgrade
|
| Impairment of Goodwill | - | - | - | -2.42 | -2.92 | -4.92 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -3.55 | 10.69 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 60.67 | 69.17 | -0 | 0.06 | -0.45 | 0 | Upgrade
|
| Asset Writedown | -27.65 | -24 | -7.47 | -0.41 | -0.5 | -3.21 | Upgrade
|
| Other Unusual Items | 14.12 | 14.4 | 9.44 | 11.53 | 5.19 | 13.86 | Upgrade
|
| Pretax Income | 251.72 | 218.13 | 174.06 | 163.84 | 197.5 | 188.89 | Upgrade
|
| Income Tax Expense | 23.33 | 17.35 | 12.01 | 2.66 | 26.27 | 23.94 | Upgrade
|
| Earnings From Continuing Operations | 228.38 | 200.79 | 162.05 | 161.18 | 171.23 | 164.95 | Upgrade
|
| Minority Interest in Earnings | -2.03 | -0.09 | 0.85 | 0.4 | -0.43 | 0.19 | Upgrade
|
| Net Income | 226.35 | 200.7 | 162.9 | 161.58 | 170.8 | 165.14 | Upgrade
|
| Net Income to Common | 226.35 | 200.7 | 162.9 | 161.58 | 170.8 | 165.14 | Upgrade
|
| Net Income Growth | 36.34% | 23.21% | 0.81% | -5.39% | 3.42% | 25.69% | Upgrade
|
| Shares Outstanding (Basic) | 323 | 329 | 326 | 330 | 328 | 326 | Upgrade
|
| Shares Outstanding (Diluted) | 323 | 329 | 326 | 330 | 328 | 326 | Upgrade
|
| Shares Change (YoY) | -0.78% | 0.99% | -1.20% | 0.67% | 0.59% | -0.09% | Upgrade
|
| EPS (Basic) | 0.70 | 0.61 | 0.50 | 0.49 | 0.52 | 0.51 | Upgrade
|
| EPS (Diluted) | 0.70 | 0.61 | 0.50 | 0.49 | 0.52 | 0.51 | Upgrade
|
| EPS Growth | 37.41% | 22.00% | 2.04% | -6.02% | 2.82% | 25.80% | Upgrade
|
| Free Cash Flow | 275.95 | 145.83 | 123.93 | -86.92 | 9.38 | 34.13 | Upgrade
|
| Free Cash Flow Per Share | 0.85 | 0.44 | 0.38 | -0.26 | 0.03 | 0.10 | Upgrade
|
| Dividend Per Share | 0.250 | 0.250 | 0.200 | 0.179 | 0.179 | 0.179 | Upgrade
|
| Dividend Growth | 25.00% | 25.00% | 11.98% | - | - | 22.50% | Upgrade
|
| Gross Margin | 70.00% | 68.48% | 63.01% | 66.75% | 69.89% | 72.77% | Upgrade
|
| Operating Margin | 21.48% | 17.28% | 17.97% | 17.61% | 22.16% | 21.71% | Upgrade
|
| Profit Margin | 28.62% | 28.09% | 24.25% | 24.67% | 24.61% | 21.78% | Upgrade
|
| Free Cash Flow Margin | 34.89% | 20.41% | 18.45% | -13.27% | 1.35% | 4.50% | Upgrade
|
| EBITDA | 277.37 | 217.99 | 198.04 | 176.89 | 208.45 | 212.46 | Upgrade
|
| EBITDA Margin | 35.07% | 30.52% | 29.49% | 27.01% | 30.04% | 28.02% | Upgrade
|
| D&A For EBITDA | 107.5 | 94.56 | 77.32 | 61.55 | 54.67 | 47.87 | Upgrade
|
| EBIT | 169.88 | 123.43 | 120.71 | 115.34 | 153.78 | 164.59 | Upgrade
|
| EBIT Margin | 21.48% | 17.28% | 17.97% | 17.61% | 22.16% | 21.71% | Upgrade
|
| Effective Tax Rate | 9.27% | 7.95% | 6.90% | 1.62% | 13.30% | 12.68% | Upgrade
|
| Revenue as Reported | 790.86 | 714.37 | 671.63 | 654.97 | 693.96 | 758.13 | Upgrade
|
| Advertising Expenses | - | 3.85 | 1.81 | 0.89 | 1.41 | 1.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.